INS and Hypoglycemia: Fewer Gla‐300 switchers experienced hypoglycaemia at 3‐ and 6‐month follow‐up (Gla‐300 switchers vs other basal insulin switchers: 3 m, 4.4% vs 8.4%, P < 0.001; 6 m, 6.0% vs 11.4%, P < 0.001).